A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis

被引：11

作者：

Anolli, Maria Paola ^{[1
]}

Degasperi, Elisabetta ^{[1
]}

Allweiss, Lena ^{[2
,3
]}

Sangiovanni, Angelo ^{[1
]}

Maggioni, Marco ^{[4
]}

Scholtes, Caroline ^{[5
,6
,7
]}

Oberhardt, Valerie ^{[8
]}

Neumann-Haefelin, Christoph ^{[8
]}

Dandri, Maura ^{[2
,3
]}

Zoulim, Fabien ^{[5
,6
,7
]}

Lampertico, Pietro ^{[1
,9
,10
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[2] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, Hamburg, Germany

[3] German Ctr Infect Res DZIF, Hamburg Lubeck Borstel Riems Site, Hamburg, Germany

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Pathol Unit, Milan, Italy

[5] Hosp Civils Lyon HCL, Hepatol Dept, Lyon, France

[6] Univ Claude Bernard Lyon 1 UCBL1, Lyon, France

[7] Ctr Rech Canc Lyon CRCL, INSERM U1052, Lyon, France

[8] Univ Freiburg, Freiburg Univ Med Ctr, Fac Med, Dept Med 2, Freiburg, Germany

[9] Univ Milan, CRC AM&A Migliavacca Ctr Liver Dis, Dept Pathophysiol & Transplantat, Milan, Italy

[10] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Via F Sforza 35, I-20122 Milan, Italy

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷 / 04期

关键词：

Bulevirtide; HDV; HDV RNA; HBV; compensated cirrhosis; sustained virological response; clinically significant portal hypertension; liver fibrosis; HBcrAg; PBMC; HEPATITIS-D; MULTICENTER; EFFICACY; SAFETY;

D O I：

10.1016/j.jhep.2022.12.023

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Bulevirtide recently received conditional approval from the EMA for the treatment of chronic hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first case of hepatitis delta cure following 3 years of bulevirtide monotherapy in a patient with compensated cirrhosis and esophageal varices. During the 72-week off-bulevirtide follow-up, virological and biochemical responses were maintained. In the off-therapy liver biopsy, intrahepatic HDV RNA and hepatitis D antigen were undetectable, <1% of hepatocytes were hepatitis B surface antigen positive and all were negative for hepatitis B core antigen. Ishak grading and staging were improved following treatment.(c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

引用

页码：876 / 880

页数：5

共 50 条

[21] BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH NON-COMPENSATED LIVER CIRRHOSIS DUE TO HEPATITIS D
Barsukova, Natalia Alexandrovna
Bogomolov, Pavel
Buyeverov, Alexey O.
Koblov, Sergei
Isaeva, Ekaterina
Kalashnikov, Michail Vladislavovich
Shub, Nadezhda Anatolyevna
Arapova, Maria Valeryevna
HEPATOLOGY, 2023, 78 : S2142 - S2142
[22] Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks
Degasperi, Elisabetta
Anolli, Maria Paola
Renteria, Sara Colonia Uceda
Sambarino, Dana
Borghi, Marta
Perbellini, Riccardo
Facchetti, Floriana
Soffredini, Roberta
Monico, Sara
Ceriotti, Ferruccio
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2023, 78 : S1159 - S1159
[23] Bariatric Surgery for Patients with Cirrhosis: Safety and 3-year Outcomes
Jamshed, Fatima
Kelly, Maureen
Mehal, Wajahat
OBESITY, 2021, 29 : 64 - 65
[24] RELATIONSHIP BETWEEN ALT NORMALIZATION RATES AND DIFFERENT VIROLOGIC RESPONSE CRITERIA IN CHRONIC HDV PATIENTS TREATED WITH BULEVIRTIDE MONOTHERAPY
Lampertico, Pietro
Aleman, Soo
Bogomolov, Pavel
Stepanova, Tatyana
Cornberg, Markus
Ciesek, Sandra
Berger, Annemarie
Manuilov, Dmitry
An, Qi
Lau, Audrey H.
Da, Ben L.
Flaherty, John F.
Mercier, Renee-Claude
Liu, Yang
Brunetto, Maurizia R.
Zeuzem, Stefan
Wedemeyer, Heiner
HEPATOLOGY, 2023, 78 : S586 - S588
[25] Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting
Shekhtman, Louis
Dahari, Harel
Cotler, Scott
Degasperi, Elisabetta
Anolli, Maria Paola
Renteria, Sara Colonia Uceda
Sambarino, Dana
Borghi, Marta
Perbellini, Riccardo
Facchetti, Floriana
Ceriotti, Ferruccio
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2022, 77 : S874 - S874
[26] Bulevirtide monotherapy in patients with chronic HDV : Efficacy and safety results through week 96 from a phase III randomized trial
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Berger, Annemarie
Ciesek, Sandra
Manuilov, Dmitry
Mercier, Renee-Claude
Da, Ben L.
Chee, Grace M.
Li, Mingyang
Flaherty, John F.
Lau, Audrey H.
Osinusi, Anu
Wiesch, Julian Schulze zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2024, 81 (04)
[27] Fate of HDV-specific CD8+T cells during bulevirtide monotherapy in patients with chronic hepatitis delta
Oberhardt, Valerie
Degasperi, Elisabetta
Borghi, Marta
Heim, Kathrin
Soffredini, Roberta
Loglio, Alessandro
Sogukpinar, Ozlem
Winkler, Frances
Bengsch, Bertram
Hofmann, Maike
Thimme, Robert
Lampertico, Pietro
Neumann-Haefelin, Christoph
JOURNAL OF HEPATOLOGY, 2022, 77 : S196 - S196
[28] Improvement of non-invasive fibrosis tests in HDV cirrhotic patients with clinically significant portal hypertension responding to Bulevirtide monotherapy
Degasperi, E.
Anolli, M. P.
Renteria, S. Uceda
Sambarino, D.
Borghi, M.
Perbellini, R.
Facchetti, F.
Monico, S.
Fraquelli, M.
Costantino, A.
Ceriotti, F.
Lampertico, P.
DIGESTIVE AND LIVER DISEASE, 2024, 56 : S34 - S34
[29] Excellent virological and clinical responses maintained over 3 years of continuous Bulevirtide treatment in patients with HDV compensated cirrhosis and clinically significant portal hypertension
Loglio, Alessandro
Ferenci, Peter
Renteria, Sara Colonia Uceda
Tham, Christine Y. L.
Holzmann, Heidemarie
Borghi, Marta
Perbellini, Riccardo
Trombetta, Elena
Giovanelli, Silvia
Porretti, Laura
Prati, Daniele
Ceriotti, Ferruccio
Bertoletti, Antonio
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2021, 75 : S746 - S746
[30] LONG- TERM BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH HDV- RELATED COMPENSATED CIRRHOSIS: EFFECTIVENESS, SAFETY AND CLNICAL OUTCOMES FROM THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY ( SAVE- D)
Degasperi, Elisabetta
Anolli, Maria Paola
Jachs, Mathias
Reiberger, Thomas
Deledinghen, Victor
Metivier, Sophie
D'Offizzi, Gianpiero
Di Maria, Francesco
Schramm, Christoph
Schmidt, Hartmut
Zoellner, Caroline
Tacke, Frank
Dietz-Fricke, Christopher
Wedemeyer, Heiner
Papatheodoridi, Margarita
Papatheodoridis, George
Carey, Ivana
Agarwal, Kosh
van Boemmel, Florian
Brunetto, Maurizia
Cardoso, Mariana
Verucchi, Gabriella
Ciancio, Alessia
Zoulim, Fabien
Aleman, Soo
Semmo, Nasser
Mangia, Alessandra
Hilleret, Marie Noelle
Loglio, Alessandro
Merle, Uta
Santantonio, Teresa Antonia
Coppola, Nicola
Pellicelli, Adriano
Roche, Bruno
Causse, Xavier
D'Alteroche, Louis
Dumortier, Jerome
Carrie, Nathalie Ganne
Heluwaert, Frederic
Ollivier, Isabelle Hourmand
Roulot, Dominique
Federico, Alessandro
Pileri, Francesca
Maracci, Monia
Tonnini, Matteo
Arpurt, Jean Pierre
Karl, Barange
Billaud, Eric
Pol, Stanislas
Gervais, Anne
HEPATOLOGY, 2024, 80 : S313 - S315

← 1 2 3 4 5 →